10-Q quarterly report · filed Nov 9, 2026

HERON THERAPEUTICS, INC. /DE/ (HRTX) Q3 2026 10-Q Quarterly Report

Short answer

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $35M (down 7.8% year over year) with net income of −$5M.

Q3 2026 key financials · XBRL

Revenue
$35M
−7.8% YoY · −6.4% QoQ
Net income
−$5M
+71.4% YoY · +8.8% QoQ
Operating margin
-4.7%
Gross margin
74.6%
EPS (diluted)
−$0.03
+72.7% YoY · +0.0% QoQ

Source: XBRL data from the HERON THERAPEUTICS, INC. /DE/ (HRTX) Q3 2026 10-Q on SEC EDGAR. USD.

HERON THERAPEUTICS, INC. /DE/ Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $35.3M, down $3.0M YoY, with acute care $15.1M vs $12.3M and oncology $20.1M vs $25.9M
  • Gross margin 74.6% vs 68.8% YoY, operating margin (4.7%) vs (10.7%)
  • Best segment acute care sales up 22.5% to $15.1M, worst oncology sales down 22.2% to $20.1M
  • Cash, cash equivalents and short-term investments $23.4M; operating cash use $4.5M versus $18.4M
  • Proposed Asset Sale expected first quarter 2027, with $145.0M cash and 14,583,333 CorMedix shares; covenant default risk remains without closing or funding

Risk Factors

  • Newly added asset-sale risk: CorMedix transaction announced November 8, 2026, requiring stockholder approval and other closing conditions
  • Most material update, liquidity: $23.4 million cash and possible covenant noncompliance could trigger debt acceleration and going-concern doubt
  • Regulatory risk: Post-sale assets may trigger Investment Company Act regulation, restricting investments, operations, and equity compensation
  • Legal risk: June 1, 2026 Azurity judgment invalidated two patents and found ten others not infringed, with appeal briefing completed November 4, 2026
  • Market risk: Nasdaq bid price below $1.00 triggered deficiency notice, with compliance required by December 22, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other HERON THERAPEUTICS, INC. /DE/ quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.